AOD-9604 in Prostki — Fat Loss Peptide Research Guide
AOD-9604 research guide for Prostki. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Prostki trying to locate AOD-9604, the foundational reality is that this compound is distributed via specialist online vendors. The core insight for Prostki researchers: sourcing AOD-9604 depends entirely on vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. A properly operating AOD-9604 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. The sections below cover what Prostki researchers need to know about finding, evaluating, and storing AOD-9604 for research purposes.
What Studies Say About AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Prostki comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade AOD-9604
Before assessing any particular supplier, establish a quality benchmark — so you can tell whether a COA is complete and credible. The HPLC purity trace is the most important document in the COA: it should show a dominant main peak representing AOD-9604, with small or absent impurity peaks representing impurities — purity should be 98% or higher. Signs of a credible vendor beyond COA quality: multi-year operating history, responsive technical support who understand testing methodology, and shipping with desiccant and appropriate cold protection. The powdered lyophilised form of AOD-9604 is much more stable than liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations lose activity within weeks.
Order AOD-9604 — ships to Prostki
COA-verified · International tracking · Research grade
AOD-9604 is sold for research purposes only and is not approved for human therapeutic use by the FDA or equivalent regulatory bodies — all information here is for educational purposes only. Temperature excursions — even brief warming above recommended storage temperature — can compromise product integrity without visible changes; always verify cold chain was maintained during shipping. The most significant preventable safety hazard in AOD-9604 research is bacterial endotoxin from low-quality material — a confirmed endotoxin test result in the lot-matched COA is the specific protection against this risk. The research literature on AOD-9604 should be studied thoroughly before beginning any research — study approaches, dose levels, and measured endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
